Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics

Journal of Clinical Psychopharmacology

Volumn 29, Issue 6, 2009, Pages 529-536

  Lin, Chao Cheng ^a   Bai, Ya Mei ^b,c   Wang, Ying Chieh ^d,e   Chen, Tzu Ting ^d   Lai, I Ching ^d,e   Chen, Jen Yeu ^d   Chen, Shiow Yi ^f   Gau, Susan S F ^a   Liou, Ying Jay ^b,c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d YULI VETERANS HOSPITAL   (Taiwan)

^e TZU CHI UNIVERSITY   (Taiwan)

^f NATIONAL TAIWAN OCEAN UNIVERSITY   (Taiwan)

Author keywords

Amisulpride; Antipsychotic; Body weight; Metabolic; Obesity

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; ZIPRASIDONE; ZOTEPINE;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INSULIN RESISTANCE; MALE; MCNEMAR TEST; METABOLIC SYNDROME X; OBESITY; OPEN STUDY; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULSE RATE; RETROSPECTIVE STUDY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; WAIST CIRCUMFERENCE; WAIST HIP RATIO; WEIGHT REDUCTION;

ADULT; ANTIPSYCHOTIC AGENTS; BODY WEIGHT; ENERGY METABOLISM; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; OBESITY; OVERWEIGHT; PROSPECTIVE STUDIES; SULPIRIDE; TREATMENT OUTCOME;

EID: 72949088912     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3181bf613e     Document Type: Article

References (60)

1. Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry. 2002;159:1018-1028. (Pubitemid 34586949)
2. Leucht S, Wahlbeck K, Hamann J, et al. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet. 2003;361:1581-1589.
3. Purdon SE, Jones BD, Stip E, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia. Arch Gen Psychiatry. 2000;57:249-258.
4. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161:414-425.
5. Schooler N, Rabinowitz J, Davidson M, et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry. 2005;162:947-953.
6. Rettenbacher MA. Disturbances of glucose and lipid metabolism during treatment with new generation antipsychotics. Curr Opin Psychiatry. 2005;18:175-179.
7. Weiden PJ, Buckley PF. Reducing the burden of side effects during long-term antipsychotic therapy: the role of Bswitching[ medications. J Clin Psychiatry. 2007;68:(suppl 6):14-23.
8. Dalmau A, Bergman B, Brismar B. Somatic morbidity in schizophreniaVa case control study. Public Health. 1997;111:393-397.
9. Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry. 1998;173:11-53.
10. Kurzthaler I, Fleischhacker WW. The clinical implications of weight gain in schizophrenia. J Clin Psychiatry. 2001;62:(suppl 7):32-37.
11. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry. 2001;62:(suppl 7):22-31.
12. Allison DB, Mackell JA, McDonnell DD. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv. 2003;54:565-567.
13. Werneke U, Taylor D, Sanders TA. Options for pharmacological management of obesity in patients treated with atypical antipsychotics. Int Clin Psychopharmacol. 2002;17:145-160.
14. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res. 2004;66:51-57.
15. De Hert MA, van WR, Van ED, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res. 2006;83:87-93.
16. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80:19-32.
17. Bai YM, Chen JY, Yang WS, et al. Adiponectin as a potential biomarker for the metabolic syndrome in Chinese patients taking clozapine for schizophrenia. J Clin Psychiatry. 2007;68:1834-1839.
18. Weiden PJ. Switching antipsychotics as a treatment strategy for antipsychotic-induced weight gain and dyslipidemia. J Clin Psychiatry. 2007;68:(suppl 4):34-39.
19. Weiden PJ, Daniel DG, Simpson G, et al. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol. 2003;23:595-600.
20. Montes JM, Rodriguez JL, Balbo E, et al. Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:383-388.
21. Casey DE, Carson WH, Saha AR, et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl). 2003;166:391-399.
22. Schoemaker H, Claustre Y, Fage D, et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther. 1997;280:83-97.
23. Delcker A, Schoon ML, Oczkowski B, et al. Amisulpride versus haloperidol in treatment of schizophrenic patientsVresults of a double-blind study. Pharmacopsychiatry. 1990;23:125-130.
24. Wetzel H, Grunder G, Hillert A, et al. Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatologyVa double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group. Psychopharmacology (Berl). 1998;137:223-232.
25. Moller HJ, Boyer P, Fleurot O, et al. Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group. Psychopharmacology (Berl). 1997;132:396-401.
26. Puech A, Fleurot O, Rein W. Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group. Acta Psychiatr Scand. 1998;98:65-72.
27. Colonna L, Saleem P, Dondey-Nouvel L, et al. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. Int Clin Psychopharmacol. 2000;15:13-22.
28. Danion JM, Rein W, Fleurot O. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. Am J Psychiatry. 1999;156:610-616.
29. Paillere-Martinot ML, Lecrubier Y, Martinot JL, et al. Improvement of some schizophrenic deficit symptoms with low doses of amisulpride. Am J Psychiatry. 1995;152:130-134.
30. Loo H, Poirier-Littre MF, Theron M, et al. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry. 1997;170:18-22.
31. Boyer P, Lecrubier Y, Puech AJ, et al. Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry. 1995;166:68-72.
32. Speller JC, Barnes TR, Curson DA, et al. One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol. Br J Psychiatry. 1997;171:564-568.
33. Peuskens J, Bech P, Moller HJ, et al. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. Psychiatry Res. 1999;88:107-117.
34. Sechter D, Peuskens J, Fleurot O, et al. Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. Neuropsychopharmacology. 2002;27:1071-1081.
35. Martin S, Ljo H, Peuskens J, et al. A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months. Curr Med Res Opin. 2002;18:355-362.
36. Mortimer A, Martin S, Loo H, et al. A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia. Int Clin Psychopharmacol. 2004;19:63-69.
37. Leucht S, Wagenpfeil S, Hamann J, et al. Amisulpride is an Batypical[ antipsychotic associated with low weight gain. Psychopharmacology (Berl). 2004;173:112-115.
38. Frankenburg FR, Zanarini MC, Kando J, et al. Clozapine and body mass change. Biol Psychiatry. 1998;43:520-524.
39. Hermans MP, Levy JC, Morris RJ, et al. Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes. Diabetologia. 1999;42:678-687.
40. Perez-Martin A, Raynaud E, Hentgen C, et al. Simplified measurement of insulin sensitivity with the minimal model procedure in type 2 diabetic patients without measurement of insulinemia. Horm Metab Res. 2002;34:102-106.
41. Alberti KG, Zimmet P, Shaw J. Metabolic syndromeVa new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med. 2006;23:469-480.
42. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:799-812.
43. Guy W. ECDEU Assessment Manual for Psychopharmacology. Rev ed. Rockville, MD: National Institute of Mental Health; 1976.
44. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11-19.
45. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
46. Fann WE, Stafford JR, Malone RL, et al. Clinical research techniques in tardive dyskinesia. Am J Psychiatry. 1977;134:759-762.
47. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1-100.
48. Moller HJ. State of the art of drug treatment of schizophrenia and the future position of the novel/atypical antipsychotics. World J Biol Psychiatry. 2000;1:204-214.
49. Linden M, Eich FX, Pyrkosch L. Do differences in atypical antipsychotics matter in routine practice? Medication switch from olanzapine and risperidone to amisulpride. Int Clin Psychopharmacol. 2007;22:175-178.
50. Rettenbacher MA, Ebenbichler C, Hofer A, et al. Early changes of plasma lipids during treatment with atypical antipsychotics. Int Clin Psychopharmacol. 2006;21:369-372.
51. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209-1223.
52. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry. 2006;163:611-622.
53. Redelmeier DA, Tan SH, Booth GL. The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med. 1998;338:1516-1520.
54. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19:(suppl 1):1-93.
55. Peuskens J, De HM, Mortimer A. Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine. Int Clin Psychopharmacol. 2007;22:145-152.
56. Rettenbacher MA, Hummer M, Hofer A, et al. Alterations of glucose metabolism during treatment with clozapine or amisulpride: results from a prospective 16-week study. J Psychopharmacol. 2007;21: 400-404.
57. Mackin P, Bishop D, Watkinson H, et al. Metabolic disease and cardiovascular risk in people treated with antipsychotics in the community. Br J Psychiatry. 2007;191:23-29.
58. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet. 2000;356: 1955-1964.
59. Paparrigopoulos T, Liappas J, Tzavellas E, et al. Amisulpride-induced hyperprolactinemia is reversible following discontinuation. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31:92-96.
60. Wu MK, Wang CK, Bai YM, et al. Outcomes of obese, clozapine-treated inpatients with schizophrenia placed on a six-month diet and physical activity program. Psychiatr Serv. 2007;58:544-550.